Therapy News and Research

RSS

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.

16 Jun 2015

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.

16 Jun 2015

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).

16 Jun 2015

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.

16 Jun 2015

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies.

16 Jun 2015

New review outlines basic principles of dietary treatment

Thanks to screening of newborns and newly developed therapies, the population of patients with inherited metabolic disorders has expanded. As these patients age and enter adulthood, diet therapy will be the mainstay of treatment for their disorders.

16 Jun 2015

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).

16 Jun 2015

WHO and World Bank Group: 400 million people do not have access to essential health services

A World Health Organization and World Bank Group report launched today shows that 400 million people do not have access to essential health services and 6% of people in low- and middle-income countries are tipped into or pushed further into extreme poverty because of health spending.

16 Jun 2015

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University has entered into a licensing agreement with a startup company, CadheRx Therapeutics, to develop and market an anti-cancer technology discovered by Sabine Brouxhon, MD, Clinical Associate Professor in the Department of Emergency Medicine at Stony Brook University School of Medicine.

16 Jun 2015

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

Although traditionally understood to induce death in cancer cells, researchers at The University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers.

16 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Scientists report that mouse with weak bones appears to have strong metabolism

One mouse with weak bones appears to have a strong metabolism, even on a high-fat diet, scientists report. While weaker bones are clearly not a good thing, scientists suspect that, somewhere in the conversation between the genetically engineered mouse's skeleton and the rest of its body, there may be an answer that helps obese individuals avoid some of the worst ravages of this health epidemic.

16 Jun 2015

SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that, after extensive review of competitive systems, The Anthony Nolan Cell Therapy Centre in Nottingham UK has chosen the SynGenXTM-1000 System and the CryoPRO Workstation to process its umbilical cord blood units. Anthony Nolan has signed a 5-year contract with Deva Medical Electronics Ltd, SynGen Inc.’s UK distributor, for the supply of SynGen’s products and all post-sales support, starting late summer 2015.

15 Jun 2015

Supporting Innovation in Life Sciences

In this interview, News-Medical speaks to Ger Brophy about the importance of supporting technological innovation in the life sciences.

15 Jun 2015

Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company's orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication.

15 Jun 2015

Genesis inks asset purchase agreement with Revera

Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has signed an asset purchase agreement with Revera Inc., a leading owner, operator and investor in the senior living sector, to acquire 24 of its skilled nursing facilities along with its contract rehabilitation business for $240 million.

15 Jun 2015

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations.

15 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us, an educational and authoritative website that offers free and in-depth resources for mesothelioma patients and their families, has just released a new case study that focuses on the experimental treatments for the disease.

15 Jun 2015

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

Living Cell Technologies Limited today announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL.

15 Jun 2015

Therapy News and Research

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

New review outlines basic principles of dietary treatment

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

WHO and World Bank Group: 400 million people do not have access to essential health services

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

Novartis presents positive Phase III results of Farydak therapy at EHA

Scientists report that mouse with weak bones appears to have strong metabolism

SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

Supporting Innovation in Life Sciences

Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Genesis inks asset purchase agreement with Revera

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News